In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Lundbeck, Teva to develop and market oral drug for MS

Executive Summary

H. Lundbeck (drugs to treat psychiatric and neurological diseases) and Teva Pharmaceuticals (generic drugs) will co-develop and co-market in Europe and several overseas markets, an oral formulation of Teva's Copaxone (glatiramer acetate).
Deal Industry
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies

UsernamePublicRestriction

Register